ПЕРСПЕКТИВЫ КАРДИОПРОТЕКЦИИ С ПОМОЩЬЮ ИШЕМИЧЕСКОГО ПРЕКОНДИЦИОНИРОВАНИЯ: ГИПОКСИЯ-ИНДУЦИРУЕМЫЙ ФАКТОР 1 — ВОЗМОЖНЫЙ МОЛЕКУЛЯРНЫЙ МЕХАНИЗМ И МИШЕНЬ ДЛЯ ФАРМАКОТЕРАПИИ

Обзор посвящен анализу современных фундаментальных исследований феномена прекондиционирования/предвоздействия в рамках ишемической болезни сердца и недостаточности кровообращения. Приведены краткие предпосылки к изучению этого феномена. Представлены молекулярно-генетические основы явления, результаты современных экспериментальных работ в области фундаментальной медицины и клинических наблюдений пациентов с различными сердечно-сосудистыми заболеваниями. Гипоксия-индуцируемый фактор 1 — основной генетический фактор адаптации к гипоксическому состоянию — играет критическую протекторную роль в патофизиологии ишемической болезни сердца и недостаточности кровообращения, контролируя и определяя доставку и использование кислорода, регулируя ангиогенез и сосудистое ремоделирование, метаболизм глюкозы и окислительно-восстановительный обмен. Технология персонализированной медицины, основанная на фармакогеномике, фармакогенетике, фармакопротеомике, позволит внедрить фундаментальные открытия в медицине в клиническую практику. 

1. The global burden of disease: 2004 update. World Health Organization 2008. 146 p.

2. Amosova EN. Metabolic therapy of myocardial damage caused by ischemia. A new approach to the treatment of coronary heart disease and heart failure. Ukr Kard J 2000; 4: 86-8. (in Russ.) Амосова Е. Н. Метаболическая терапия повреждений миокарда, обусловленных ишемией. Новый подход к лечению ишемической болезни сердца и сердечной недостаточности. Укр Кард Журнал 2000; 4: 86-8.

3. Lyubimov AV, Cherkashin DV. Cardioprotective possibilities pro-hypoxic preconditioning. Morskaya Medicina 2016; 2 (4): 20-9. (in Russ.) Любимов А. В., Черкашин Д. В. Кардиопротекторные возможности прогипоксического прекондиционирования. Морская медицина 2016; 2 (4): 20-9.

4. Oganov RG, Lepakhin VK, Fitilev SB, et al. Diagnosis and Therapy of Stable Angina in Russian Federation (International Study ATP — Angina Treatment Pattern). Kardiologiia 2003; 5: 9-15. (in Russ.) Оганов Р. Г., Лепахин В. К., Фитилев С. Б. и др. Особенности диагностики и терапии стабильной стенокардии в Российской Федерации (международное исследование АТР — Angina Treatment Pattern). Кардиология 2003; 5: 9-15.

5. Fox KM, Mulcahy D, Findlay I, et al. On behalf of the TIBET Study Group. The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and total ischaemic burden in 608 patients with stable angina. Eur Heart J 1996; 17: 96-103.

6. Shlyakhto EV, Nifontov EM, Galagudza MM. Limitation of ischemic and reperfusion injury of the myocardium by pre- and post-coding: molecular mechanisms and targets for pharmacotherapy. Creative Cardiology 2007; 1-2: 75-101. (in Russ.) Шляхто Е. В., Нифонтов Е. М., Галагудза М. М. Ограничение ишемического и реперфузионного повреждения миокарда с помощью пре- и посткондиционирования: молекулярные механизмы и мишени для фармакотерапии. Креативная кардиология 2007; 1-2: 75-101.

7. Ferrari R. Metabolic treatment of myocardial ischaemia. Eur Heart J 1999; 20: 1144-5.

8. Kuibler W. Cardioprotection: definition, classification, and fundamental principles Markus Haass Heart 1996; 75: 330-3.

9. Teslev AA, Sorokin VV, Minina SA, et al. Modern metabolic cardioprotectors. Technological aspects of the development of drugs on their basis. Belgorod State University Scientific bulletin Series Medicine. Pharmacy 2014; 4 (175,25): 188-95. (in Russ.) Теслев А. А., Сорокин В. В., Минина С. А. и др. Современные метаболические кардиопротекторы. Технологические аспекты разработки лекарственных препаратов на их основе. Научные ведомости БелГУ Серия Медицина. Фармация 2014; 4 (175,25): 188-95.

10. Shlyakhto EV, Konradi AO, Galagudza MM. Translational medicine: yesterday, today, tomorrow. Vestnik Roszdravnadzora 2016; 1: 47-51. (in Russ.) Шляхто Е. В., Конради А. О., Галагудза М. М. Трансляционная медицина: вчера, сегодня, завтра. Вестник Росздравнадзора 2016; 1: 47-51.

11. Message of the President of the Russian Federation to the Federal Assembly of December 12, 2013. Moscow, Kremlin. 2013. (in Russ.) Послание Президента РФ Федеральному Собранию от 12.12.2013 “Послание Президента РФ Владимира Путина Федеральному Собранию”. Москва, Кремль. 2013.

12. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270: 1230-7. [PubMed: 7836384].

13. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helixloophelixPAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-4. [PubMed: 7539918].

14. Iyer NV, Kotch LE, Agani F, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1α. Genes Dev 1998; 12: 149-62. [PubMed: 9436976].

15. Compernolle V, Brusselmans K, Franco D, et al. Cardia bifida, defective heart development and abnormal neural crest migration in embryos lacking hypoxiainducible factor-1α. Cardiovasc Res 2003; 60: 569-79. [PubMed: 14659802]

16. Yoon D, Pastore YD, Divoky V, et al. Hypoxia-inducible factor 1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development. J Biol Chem 2006; 281: 25703-11. [PubMed: 16787915].

17. Lage K, Greenway SC, Rosenfeld JA, et al. Genetic and environmental risk factors in congenital heart disease functionally converge in protein networks driving heart development. Proc Natl Acad Sci USA 2012; 109: 14035-40. [PubMed: 22904188].

18. Bergeron M, Yu AY, Solway KE, et al. Induction of hypoxia-inducible factor-1 (HIF-1) and its target genes following focal ischaemia in rat brain. Eur J Neurosci 1999; 11: 4159-70. [PubMed: 10594641].

19. Martin C, Yu AY, Jiang BH, et al. Cardiac hypertrophy in chronically anemic fetal sheep: Increased vascularization is associated with increased myocardial expression of vascular endothelial growth factor and hypoxia-inducible factor 1. Am J Obstet Gynecol 1998; 178: 527-34. [PubMed: 9539521].

20. Lee SH, Wolf PL, Escudero R, et al. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med 2000; 342: 626-33. [PubMed: 10699162].

21. Jurgensen JS, Rosenberger C, Wiesener MS, et al. Persistent induction of HIF-1α and -2α in cardiomyocytes and stromal cells of ischemic myocardium. FASEB J 2004; 18: 1415-7. [PubMed: 15247145].

22. Wiener CM, Booth G, Semenza GL. In vivo expression of mRNAs encoding hypoxiainducible factor 1. Biochem Biophys Res Commun 1996; 225: 485-88. [PubMed: 8753788].

23. Rosenberger C, Mandriota S, Jurgensen JS, et al. Expression of hypoxia-inducible factor 1α and 2α in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 2002; 13: 1721-32. [PubMed: 12089367].

24. Wiener CM, Booth G, Semenza GL. In vivo expression of mRNAs encoding hypoxiainducible factor 1. Biochem Biophys Res Commun 1996; 225: 485-8. [PubMed: 8753788].

25. Yu AY, Frid MG, Shimoda LA, et al. Temporal, spatial, and oxygenregulated expression of hypoxia-inducible factor 1 in the lung. Am J Physiol Lung Cell Mol Physiol 1998; 275: L818-26.

26. Bosch-Marcе M, Okuyama H, Wesley JB, et al. Effects of aging and hypoxia-inducible factor 1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. Circ Res 2007; 101: 1310-8. [PubMed: 17932327].

27. Kelly BD, Hackett SF, Hirota K, et al. Cell type–specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 2003; 93: 1074- 81. [PubMed: 14576200].

28. Rivard A, Fabre JE, Silver M, et al. Age-dependent impairment of angiogenesis. Circulation 1999; 99:111-20. [PubMed: 9884387].

29. Iyer NV, Kotch LE, Agani F, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1α. Genes Dev 1998; 12:149-62. [PubMed: 9436976].

30. Hinkel R, Lebherz C, Fydanaki M, et al. Angiogenetic potential of Ad2/ Hif-1α/VP16 after regional application in a preclinical pig model of chronic ischemia. Curr Vasc Pharmacol 2013; 11: 29-37. [PubMed: 23391420].

31. Kilian EG, Sadoni S, Vicol C, et al. Myocardial transfection of hypoxiainducible factor 1α via an adenoviral vector during coronary artery bypass grafting. A multicenter phase I and safety study. Circ J 2010; 74: 916-24. [PubMed: 20215699].

32. Resar JR, Roguin A, Voner J, et al. Hypoxia-inducible factor 1α polymorphism and coronary collaterals in patients with ischemic heart disease. Chest 2005; 128: 787- 91. [PubMed: 16100168].

33. Hlatky MA, Quertermous T, Boothroyd DB, et al. Polymorphisms in hypoxia inducible factor 1 and the initial clinical presentation of coronary disease. Am Heart J 2007; 154: 1035-42. [PubMed: 18035072].

34. Duran J, Gotzens V, Carballo J, et al. The HIF1A C85T polymorphism influences the number of branches of the human coronary tree. Cardiology 2012; 121: 156-9. [PubMed: 22441426].

35. Nallamothu BK, Bradley EH, Krumholz HM. Time to treatment in primary percutaneous coronary intervention. N Engl J Med 2007; 357: 1631-8. [PubMed: 17942875].

36. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Investig 1985; 76: 1713-9. [PubMed: 4056048].

37. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36. [PubMed: 3769170].

38. Kuzuya T, Hoshida S, Yamashita N, et al. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 1993; 72: 1293-9. [PubMed: 8495557].

39. Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 1993; 88: 1264-72. [PubMed: 8353888].

40. Liu GS, Thornton J, Van Winkle DM, et al. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 1991; 84: 350-6. [PubMed: 2060105].

41. Cai Z, Zhong H, Bosch-Marce M, et al. Complete loss of ischaemic preconditioninginduced cardioprotection in mice with partial deficiency of HIF-1α. Cardiovasc Res 2008; 77: 463-70. [PubMed: 18006459].

42. Sarkar K, Cai Z, Gupta R, et al. Hypoxia-inducible factor 1 transcriptional activity in endothelial cells is required for acute phase cardioprotection induced by ischemic preconditioning. Proc Natl Acad Sci USA 2012; 109: 10504-9. [PubMed: 22699503].

43. Jiang BH, Zheng JZ, Leung SW, et al. Transactivation and inhibitory domains of hypoxia-inducible factor 1α. Modulation of transcriptional activity by oxygen tension. J Biol Chem 1997; 272: 19253-60. [PubMed: 9235919].

44. Cai Z, Manalo DJ, Wei G, et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003; 108: 79-85. [PubMed: 12796124].

45. Xi L, Taher M, Yin C, et al. Cobalt chloride induces delayed cardiac preconditioning in mice through selective activation of HIF-1α and AP-1 and iNOS signaling. Am J Physiol Heart Circ Physiol 2004; 287: H2369-75. [PubMed: 15284066].

46. Ockaili R, Natarajan R, Salloum F, et al. HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation. Am J Physiol Heart Circ Physiol 2005; 289: H542-8. [PubMed: 15805230].

47. Jung F, Palmer LA, Zhou N, Johns RA. Hypoxic regulation of inducible nitric oxide synthase via hypoxia-inducible factor 1 in cardiac myocytes. Circ Res 2000; 86: 319- 25. [PubMed: 10679484].

48. Semenza GL. Regulation of metabolism by hypoxia-inducible factor 1. Cold Spring Harb Symp Quant Biol 2011; 76: 347-53. [PubMed: 21785006].